-
Democrats, Trump hold final rallies before midterm elections
-
African players in Europe: Defender Hakimi's historic hat-trick
-
Japan urges US to enforce discipline after second Marine arrest
-
Struggling Slavia face Arsenal as grim record looms
-
'Remarkable' rookie Lendeborg scores 37 as Warriors beat Clippers
-
Vikings suffer first loss while Broncos edge Chiefs in NFL
-
ExxonMobil urged to re-think Papua New Guinea gas project
-
South Korea to double spending on AI and chips in 2027
-
Asian stocks mixed as tech sector struggles to rebound from selloff
-
On All Saints' Day, Philippine mountain town honours dead with fire
-
India's royals find new power in their past
-
Years on from fall of IS, French jihadists face justice in Iraq
-
Irish bookshops help meet UK demand for Sally Rooney novels
-
Point of Law favourite at Australia's 'race that stops a nation'
-
NFL Vikings suffer first loss while Broncos edge Chiefs
-
'Kid' Antonelli gets affectionate tributes from all quarters
-
Host of fresh faces in Australia white-ball squads to face England
-
Hamilton accuses Leclerc of wrecking Ferrari hopes
-
NFL linebacker Campbell to remain hospitalized overnight
-
Chervon Names Jody Grimsley Senior National Account Manager
-
BioLargo's Clyra Medical Gains Commercial Traction as Clinician Enthusiasm Drives Health System Adoption
-
enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
-
Gladstone Alternative Income Fund Announces Monthly Cash Distribution for November 2026
-
Nexscient Announces Expanded Customer Engagements and New Commercial Agreements in Autonomous Driving and Humanoid Robotics Data Services
-
Vicapsys Life Sciences Provides Shareholder Update on VICAPSYN(TM) Program Advancing Toward Phase 1 Human Clinical Trial, Vertically Integrated With the Company's Indian Health Service Strategy
-
XCF Global Withdraws Reverse Stock Split Proposal; Reaffirms Growth Strategy and Shareholder Support
-
Gladstone Commercial Corporation Earnings Call and Webcast Information
-
cbdMD Completes Acquisition of the Operating Assets and Brands of Twinlab, including Twinlab, Reserveage and Metabolife Brands, Expanding Into Broader Wellness
-
Palo Alto Collaboration Company Opens Waitlist for Pana, a Personal AI That Builds Tools That Stay Yours
-
Anthony, Linder & Cacomanolis Recognized in Chambers & Partners Spotlight Florida 2027 for Securities Law Excellence
-
Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
-
IRS Pushes Tax Deadlines to February 1, 2027 for Washington Wildfire Counties - Clear Start Tax Explains What the Postponement Does Not Pause
-
Optimistivity Unveils Refreshed Brand and Expanded Digital Product Range
-
GameSquare to Report Q3 2026 Financial Results on November 16, 2026
-
AsiaFIN Holdings Corp. to Host Q3 2026 Earnings Webcast from New York City
-
Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
-
Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
-
iAsk.ai Surpasses One Billion Searches
-
International Battery Metals Announces Second Quarter Fiscal 2027 Financial Results Conference Call and Webcast
-
Electrovaya Ranks Fourth Among Canada's Enterprise - Industry Leaders in Deloitte's Technology Fast 50(TM) Program
-
BEING rather than HAVING. A fascinating, practical STORY.
-
Hospital AI Funding Faces a Reality Check: New 2027 Outlook Puts Outsourcing Savings to the Test
-
Jaguar Mining Provides Update on Permitting of the Onças de Pitangui Development Project, Minas Gerais, Brazil
-
Ur-Energy Announces Retirement of CFO Roger Smith, Names VP Finance Jade Walle as Successor
-
DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
-
Aer Lingus and MTech Mobility Launch Live Ground Operations Technology Programme Across Three Irish Airports
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 02
-
Bank of San Francisco Reports Third Quarter 2026 Financial Results
-
Aegis Capital Corp. Announces the Hiring of a New Managing Director
-
Foundation Software Announces Keynote Speakers for Its All-User Conference, CONVERGE27
Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
S.F.Warren--AMWN